03 August 2009
Martinsried, Germany - Affectis Pharmaceuticals, a biopharmaceutical company developing novel drugs for the treatment of psychiatric and inflammatory disorders, today announced the appointment of Alex Martin as Chief Financial Officer. Mr. Martin brings over 20 years experience in the life sciences industry, most recently serving as Chief Operating Officer of Intercept Pharmaceuticals.
Herbert Stadler, founder and CEO of Affectis, commented, "We are please to have Alex join our team as he brings experience as both a CFO and an operating manager which will be invaluable as we continue to advance our pipeline and invest in our programs further."
Mr. Martin has worked in various commercial capacities at Novartis and SmithKline Beecham (now GSK), and has helped raise venture capital financing for three previous start-ups, two of which went public.
"I am excited to be joining Affectis at this time and look forward continuing to build on the CNS foundation laid down by the management and investors," Mr. Martin added.
Contacts for Affectis Pharmaceuticals AG:
Luc St-Onge
Fraunhoferstr. 13
82152 Martinsried, Germany
Tel: +49 (0)89 - 893 2811 100
Fax: +49 (0)89 - 893 2811 111
Email:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.affectis.com
Ines-Regina Buth
akampion
Platz vor dem Neuen Tor 2
10115 Berlin, Germany
Tel: +49 (0)30 2363 2768
Fax: +49 (0)30 2363 2769
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Notes to Editors
About Affectis Pharmaceuticals AG:
Affectis is a biopharmaceutical company implementing novel concepts for the treatment of psychiatric disorders and inflammatory diseases. The Company has unique capabilities to discover and develop drugs based on pioneering findings in the field of depression, schizophrenia, and inflammation. These drugs address the increasing need for more comprehensive and faster-acting antidepressants with fewer side effects. Affectis started operations in 2004 as a spin-off from the renowned Max-Planck-Institute of Psychiatry, a world leader in the field of psychiatric research. A strong team of executives and scientists with long-term industry experience contribute to Affectis’ progress. The Company raised its third round of venture financing in October 2006, led by AESCAP Venture. Affectis is based in Munich, Germany.
For more information, please visit our website at: www.affectis.com
| File | File size |
|---|---|
 Affectis - Alex Martin CFO Aug 3 2009 | 25 Kb |
Copyright © 2010 Affectis Pharmaceuticals AG. All Rights Reserved.
